Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 1,2-dihydro-6-methyl-2-oxo-5-(imidazo(1,2-a)pyridin-6-yl)-3-pyridinecarbonitrile
2. E 1020
3. E-1020
4. Loprinone Hydrochloride
1. 106730-54-5
2. Loprinone
3. Olprinone [inn]
4. 5-imidazo[1,2-a]pyridin-6-yl-6-methyl-2-oxo-1h-pyridine-3-carbonitrile
5. 4y8bmi9ygc
6. Olprinone (inn)
7. 5-(imidazo[1,2-a]pyridin-6-yl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carbonitrile
8. 5-{imidazo[1,2-a]pyridin-6-yl}-6-methyl-2-oxo-1,2-dihydropyridine-3-carbonitrile
9. Loprinone [mi]
10. Unii-4y8bmi9ygc
11. Olprinone [who-dd]
12. Schembl27661
13. Chembl1474900
14. Dtxsid1048461
15. Chebi:135019
16. Bcp09781
17. Hy-14254a
18. S5539
19. Zinc38192538
20. 1,2-dihydro-5-imidazo(1,2-alpha)pyridin-6-yl-6-methyl-2-oxonicotinonitrile
21. Ccg-266964
22. Cs-1190
23. Sdccgsbi-0633821.p001
24. Ncgc00162385-01
25. Ncgc00162385-02
26. Ncgc00162385-03
27. Ncgc00162385-05
28. Ncgc00162385-10
29. Ac-35198
30. As-73630
31. Db-040705
32. 4606a
33. Ft-0631041
34. C71263
35. D08294
36. Q7088538
37. Brd-k20745393-001-01-4
38. 1,2-dihydro-5-(imidazo[1,2-a]-pyridin-6-yl)-6-methyl-2-oxo-3-pyridinecarbonitrile
39. 1,2-dihydro-5-(imidazo[1,2-a]pyridin-6-yl)-6-methyl-2-oxo-3-pyridinecarbonitrile
40. 1,2-dihydro-5-imidazo(1,2-.alpha.)pyridin-6-yl-6-methyl-2-oxonicotinonitrile
41. 1,2-dihydro-5-imidazo(1,2-alpha)pyridin-6-yl-6-methyl-2-oxonicotinonitrile.
42. 1,2-dihydro-6-methyl-2-oxo-5-(imidazo[1,2-a]pyridin-6-yl)-3-pyridine Carbonitrile
43. 1,2-dihydro-6-methyl-2-oxo-5-(imidazo[1,2-a]pyridin-6-yl)-3-pyridinecarbonitrile
44. 1,2-dihydro-6-methyl-5-(imidazo[1,2-a]pyridin-6-yl)-2-oxo-3-pyridinecarbonitrile
Molecular Weight | 250.25 g/mol |
---|---|
Molecular Formula | C14H10N4O |
XLogP3 | 1.5 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 3 |
Rotatable Bond Count | 1 |
Exact Mass | 250.08546096 g/mol |
Monoisotopic Mass | 250.08546096 g/mol |
Topological Polar Surface Area | 70.2 Ų |
Heavy Atom Count | 19 |
Formal Charge | 0 |
Complexity | 525 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Cardiotonic Agents
Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE). (See all compounds classified as Cardiotonic Agents.)
Phosphodiesterase 3 Inhibitors
Compounds that specifically inhibit PHOSPHODIESTERASE 3. (See all compounds classified as Phosphodiesterase 3 Inhibitors.)
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?